Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors

Hargrave, Darren; Marshall, Lynley V.; André, Nicolas; Krystal, Julie; Ladle, Brian H.; Robbins, Karen A.; Hois, Stephan; Armstrong, Jon; Donegan, Sarah

doi:10.3389/fonc.2026.1680081

Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors

Purpose We conducted a phase I/II study to evaluate durvalumab (D; anti-PD-L1) in combination with tremelimumab (T; anti–cytotoxic T-lymphocyte antigen 4) in pediatric patients with relapsed/refractory solid tumors. Patients and methods The dose-finding phase (phase I) assessed the safety and pha…